NIPER, Mohali Director given suspension orders

Published On 2018-09-26 11:08 GMT   |   Update On 2018-09-26 11:08 GMT

Chandigarh: Professor Raghuram Rao Akkinepally, the director of the National Institute of Pharmaceuticals Education and Research (NIPER), Mohali has been suspended by NIPER's Board of Governors. The move comes soon after the director refused to revoke the suspension order handed over by him to the registrar of the institute.


Raghuram Rao was given a show-cause letter issued by the government after he failed to implement the orders given by the NIPER’s Board of Governors (BoGs) where it asked him to revoke the suspension letter of the institute’s registrar.


On June 13, 2018, Raghuram Rao Akkinepally, gave a suspension to the institute’s registrar, PJP Singh Waraich (retd) alleging him for acts of omission and commission that included the misuse of official accommodation for commercial interests. The registrar appealed against the suspension before the BoG. BoG ordered the director to revoke the suspension order earlier in the month of June 2018. However, the director moved toward the High Court against the order. For the same, he has also issued a show-cause notice in August


Now, an order issued by the BoG’s chairman, Dr VM Katoch, stated, “The Board of Governors has decided to place Prof Akkinepally under suspension with immediate effect.”


Earlier, the director had been served a show-cause notice for failure to implement the board’s June 14 order to revoke the suspension of the registrar, Wg Cdr PJP Waraich, reported  Tribune ,


Professor Raghuram Rao, who was the faculty member of at the department of pharmacy at Kakatiya University. He received the designation of director of NIPER after the approval of then-President Pranab Mukherjee


He also got in on the issue where he was accounted for holding a dual post at the same time. He joined NIPER on May 10, 2017, to August 13, 2017, when he was on extraordinary leave from Kakatiya University, Warangal. His voluntary retirement from the University came in effect from August 31, 2017.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News